Cumberland Pharmaceuticals Inc. - Common Stock (CPIX)
5.0100
+0.5700 (12.84%)
NASDAQ · Last Trade: Nov 5th, 11:32 PM EST
News & Press Releases
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Cumberland Pharmaceuticals (CPIX)
NEW YORK CITY, NY / ACCESS Newswire / November 5, 2026 / Cumberland Pharmaceuticals (NASDAQ:CPIX) shareholders lost almost 48.8% of their investment on October 26, 2026, after the Company reported that its Phase 2a ASSIST-SSc pilot study of ifetroban did not produce a clear efficacy signal. If you suffered a loss on your Cumberland Pharmaceuticals investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
By Levi & Korsinsky, LLP · Via ACCESS Newswire · November 5, 2026
CPIX Investors Have Opportunity to Join Cumberland Pharmaceuticals Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cumberland Pharmaceuticals Inc. (“Cumberland” or “the Company”) (NASDAQ: CPIX) for violations of the securities laws.
By Schall, Brown & Schwartz LLP · Via Business Wire · November 5, 2026
Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathymarketbeat.com
Cumberland Pharmaceuticals (NASDAQ:CPIX) said it plans to begin a rolling New Drug Application submission for Dyscorban, its ifetroban candidate for cardiomyopathy associated with Duchenne muscular dystrophy, after the U.S. Food and Drug Administration granted the company’s request for rolling revie
Via MarketBeat · October 26, 2026
Cumberland Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
Cumberland Pharmaceuticals (NASDAQ:CPIX) reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business following the sale of its branded U.S. commercial portfolio to
Via MarketBeat · August 4, 2026
What's going on in today's pre-market sessionchartmill.com
Via Chartmill · May 21, 2026
Cumberland (CPIX) Q4 2025 Earnings Call Transcriptfool.com
Cumberland (CPIX) Q4 2025 Earnings Call Transcript
Via The Motley Fool · March 3, 2026
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · September 19, 2025
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · May 6, 2025
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · March 21, 2025
Top movers analysis one hour before the close of the markets on 2025-02-19: top gainers and losers in today's session.chartmill.com
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Via Chartmill · February 19, 2025
Here are the top movers in Wednesday's session.chartmill.com
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · February 5, 2025
What's going on in today's sessionchartmill.com
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.
Via Chartmill · February 5, 2025
What's going on in today's after hours sessionchartmill.com
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · February 4, 2025
Top movers analysis one hour before the close of the markets on 2025-02-04: top gainers and losers in today's session.chartmill.com
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · February 4, 2025
Discover the top movers in Tuesday's pre-market session.chartmill.com
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · February 4, 2025
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Diseasebenzinga.com
Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.
Via Benzinga · February 4, 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 10, 2024
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earningsbenzinga.com
Via Benzinga · December 10, 2024